Go to ...

ModernGraham

Value Investing Research Since 2006

RSS Feed

Sunday, October 22, 2017

Archives for June 2014

Vertex Pharmaceuticals Annual Valuation – 2014 $VRTX

Vertex Pharmaceuticals does not qualify for either the Defensive Investor or the Enterprising Investor. The Defensive Investor has major concerns with the lack of earnings stability over the last ten years, the lack of dividends, the insufficient earnings growth, and the high PEmg and PB ratios.

Older Posts››